ABSTRACT
Immune checkpoint inhibitors have demonstrated the ability to significantly improve survival across a range of cancers. So predictive markers are required to guide treatment decisions. The lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. The pre-treatment LIPI is a convenient prognostic marker able to identify ICIs-treated patient groups with significantly different survival and response outcomes.
ABSTRACT
Objective To compare the clinical effects and adverse effects of microwave ablation (MWA) with sorafenib and sorafenib monotherapy in the treatment of advanced-stage hepatocellular carcinoma (HCC).Methods Medical records and follow-up information of 57 patients with advanced-stage HCC were retrospectively reviewed.25 patients were treated with MWA combined with sorafenib (combined group),and 32 patients were treated with sorafenib monotherapy (monotherapy group).The end points were therapeutic effect,progression-free survival (PFS),overall survival (OS) and adverse reactions.Results The objective response rate in the combined group was similar to the monotherapy group (16.0％ vs.3.1％,x2 =1.521,P =0.217).The disease control rate in the combined group was significantly higher than that in the monotherapy group (80.0％ vs.50.0％,χ2 =5.429,P =0.020).The median PFS in the combined group was longer than that in the monotherapy group (6.0 months vs.3.2 months,x2 =7.675,P =0.006),but the median OS was similar (11.5 months vs.8.5 months,x2 =2.480,P =0.115).The serious adverse reactions were similar between the two treatment groups (44.0％ vs.34.4％,x2 =0.549,P =0.459).Conclusion MWA plus sorafenib is superior to sorafenib alone with respect to PFS in patients with advanced-stage HCC,although it may not improve OS,with no increased risk of serious adverse reactions.
ABSTRACT
ObjectiveTo explore the efficacy and toxicity of nimotuzumab plus chemotherapy in the treatment of metastatic gastrointestinal tumor.MethodsObservationgroup 22 patients with metastatic gastrointestinal tumor with confirmed diagnosis,were treated with nimotuzumab in combination chemotherapy.Nimotuzumab was given 200 mg weekly for at least six weeks. Control group 21 patients with metastatic gastrointestinal tumor with confirmed diagnosis were treated with only chemotherapy.ResultsThe effects of observation group could be observed in 22 patients, the rate of response(RR)was 31.8％ (7/22), and the disease control rate (DCR) was 72.7 ％ (16/22).QOL was improved.The effects of observation group could be observed in 21 patients,RR was 14.3 ％ (3/21),and the disease control rate was 42.8 ％ (19/21).DCR and QOL improvements were statistically significant different between the two groups.(x2=3.939,x2=4.250,P＜0.05).The two groups had no significant difference in RR and toxicity.ConclusionNimotuzumab in combination with chemotherapy is effective and can improve the disease control rate, toxicity, tolerance,quality of life.
ABSTRACT
<p><b>BACKGROUND</b>There is no effective regimen for recurrent small cell lung cancer patients now. The aim of this study is to assess the activity and toxicity of topotecan combined with cisplatin in the treatment of recurrent small cell lung cancer patients.</p><p><b>METHODS</b>Twenty-eight patients with progressive disease after one first-line regimen enrolled in the study from May 2002 to October 2004. Topotecan was given at the dose of 1.2mg/m² from 1st to 4th days and cisplatin was administered at the dose of 25mg/m² from 5th to 7th days in a cycle of 3 weeks. The patients could be evaluated at least after 2 cycles.</p><p><b>RESULTS</b>One patient got complete response and ten patients got partial response in this group. The overall response rate was 39.3% , and the response rate of refractory group and sensitive group was 37.5% (3/8) and 40.0% (8/20) respectively. The median time to progression was 4.2 months. The main toxicity was hematological toxicity. Grade III+IV neutropenia occurred in 42.9% (12/28) of the patients.</p><p><b>CONCLUSIONS</b>The regimen of topotecan and cisplatin shows better activity in retreated small cell lung cancer patients. The main toxicity is hematological toxicity and can be tolerated.</p>
ABSTRACT
Purpose:To observe the efficacy of capecitabi ne in the treatment of relapsed breast cancer. Methods:21 patients with relapsed breast cancer were treated. C apecitabine was administered twice a day at the dose of 2 500 mg/(m 2?d) f or two weeks. 21 days was one cycle. Patients could be evaluated after at least 2 cycles treatment. Results:20 patients could be evaluated. There were no complete response but 6 partial response, 8 stable disease and 6 progressive disease in t he group. The response rate was 30.0%. The common toxic effects were hand-foot syndrome (61.1%), nausea and vomiting(66.7%), leucopenia (42.9%) and skin pigm entation (23.8%). Conclusions:Capecitabine is effective for the relapsed breast c ancer patients who have been treated with anthracycline and taxanes. The toxic e ffects are mild and the tolerance is well. Capecitabine can be used as the secon d line regimen for relapsed breast cancer.
ABSTRACT
Objective To study the possibility of the exist of specific antibody against platelet in tumor patients and to evaluate the value of MAIPA in measure of specific antibody against platelet in malignant tumor patients with nonimmune thrombocytopenic purpura. Methods Anti- GPⅡb/Ⅲa and anti- GPⅠb/Ⅸ autoantibodies were detected by a modified monoclonal antibody immobilization of platelet antigens assay(modified MAIPA). Results The positive rate of the platelet antibody in nonimmune thrombocytopenic purpura is very low with MAIPA. Conclusions The platelet GP- specific autoantibody detection is considerably important in discriminating immune from nonimmune thrombocytopenia.